Wolverine Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.46M | Buy |
27,100
+5,600
| +26% | +$320K | ﹤0.01% | 2496 |
|
|
2025
Q2 | $1.19M | Sell |
21,500
-2,100
| -9% | -$124K | ﹤0.01% | 2149 |
|
|
2025
Q1 | $1.69M | Buy |
23,600
+2,000
| +9% | +$135K | ﹤0.01% | 1760 |
|
|
2024
Q4 | $1.41M | Sell |
21,600
-2,800
| -11% | -$188K | ﹤0.01% | 2308 |
|
|
2024
Q3 | $1.72M | Buy |
+24,400
| New | +$2.04M | ﹤0.01% | 1833 |
|
|
2024
Q2 | – | Sell |
-13,000
| Closed | -$1.14M | – | 4507 |
|
|
2024
Q1 | $1.14M | Buy |
+13,000
| New | +$1.16M | ﹤0.01% | 2098 |
|
|
2023
Q4 | – | Sell |
-7,700
| Closed | -$681K | – | 4503 |
|
|
2023
Q3 | $681K | Sell |
7,700
-14,200
| -65% | -$1.26M | ﹤0.01% | 2460 |
|
|
2023
Q2 | $1.95M | Buy |
21,900
+11,600
| +113% | +$1.09M | ﹤0.01% | 1482 |
|
|
2023
Q1 | $981K | Sell |
10,300
-8,600
| -46% | -$892K | ﹤0.01% | 1912 |
|
|
2022
Q4 | $1.96M | Buy |
18,900
+6,500
| +52% | +$610K | ﹤0.01% | 1401 |
|
|
2022
Q3 | $1.05M | Sell |
12,400
-3,600
| -23% | -$321K | ﹤0.01% | 1911 |
|
|
2022
Q2 | $1.34M | Buy |
16,000
+4,600
| +40% | +$366K | ﹤0.01% | 1682 |
|
|
2022
Q1 | $888K | Sell |
11,400
-6,400
| -36% | -$535K | ﹤0.01% | 2568 |
|
|
2021
Q4 | $1.59M | Sell |
17,800
-17,000
| -49% | -$1.4M | ﹤0.01% | 2108 |
|
|
2021
Q3 | $2.67M | Sell |
34,800
-4,000
| -10% | -$316K | ﹤0.01% | 1841 |
|
|
2021
Q2 | $3.24M | Buy |
38,800
+6,100
| +19% | +$484K | 0.01% | 1518 |
|
|
2021
Q1 | $2.45M | Sell |
32,700
-14,200
| -30% | -$1.16M | ﹤0.01% | 1735 |
|
|
2020
Q4 | $4.08M | Buy |
46,900
+9,000
| +24% | +$714K | 0.01% | 1208 |
|
|
2020
Q3 | $2.88M | Buy |
37,900
+2,600
| +7% | +$263K | 0.01% | 1200 |
|
|
2020
Q2 | $4.31M | Buy |
35,300
+6,300
| +22% | +$626K | 0.01% | 894 |
|
|
2020
Q1 | $2.39M | Buy |
29,000
+4,400
| +18% | +$379K | 0.01% | 1209 |
|
|
2019
Q4 | $2.08M | Buy |
24,600
+2,500
| +11% | +$189K | 0.01% | 1803 |
|
|
2019
Q3 | $1.51M | Buy |
+22,100
| New | +$1.7M | ﹤0.01% | 1645 |
|
|
2019
Q2 | – | Sell |
-36,300
| Closed | -$3.23M | – | 4425 |
|
|
2019
Q1 | $3.23M | Buy |
36,300
+13,300
| +58% | +$1.23M | 0.01% | 1161 |
|
|
2018
Q4 | $1.92M | Sell |
23,000
-11,500
| -33% | -$1.09M | 0.01% | 1443 |
|
|
2018
Q3 | $3.35M | Buy |
34,500
+12,700
| +58% | +$1.27M | 0.01% | 1246 |
|
|
2018
Q2 | $1.77M | Hold |
21,800
| – | – | ﹤0.01% | 1698 |
|
|
2018
Q1 | $1.77M | Buy |
21,800
+6,200
| +40% | +$532K | ﹤0.01% | 1698 |
|
|
2017
Q4 | $1.39M | Buy |
15,600
+11,900
| +322% | +$1.03M | 0.01% | 1852 |
|
|
2017
Q3 | $344K | Buy |
+3,700
| New | +$327K | ﹤0.01% | 3083 |
|
|
2017
Q1 | – | Sell |
-6,000
| Closed | -$497K | – | 4277 |
|
|
2016
Q4 | $497K | Sell |
6,000
-8,700
| -59% | -$748K | ﹤0.01% | 2632 |
|
|
2016
Q3 | $1.36M | Sell |
14,700
-2,500
| -15% | -$235K | 0.01% | 1595 |
|
|
2016
Q2 | $1.35M | Buy |
+17,200
| New | +$1.46M | 0.01% | 1369 |
|
Other funds holding BMRN
Wolverine Trading's BMRN Position: Q3 2025 in Review
Wolverine Trading increased its BioMarin Pharmaceuticals (BMRN) stake by 66% in Q3 2025, buying an estimated $191K and bringing the position to 8,435 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.
Wolverine Trading first reported a position in BMRN in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.76M in Q4 2021. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.
- Wolverine Trading held 8,435 shares of BioMarin Pharmaceuticals worth $456K as of Q3 2025.
- Wolverine Trading bought 3,346 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $191K.
- BioMarin Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3817 holding.
- Wolverine Trading first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 23 quarters since.
- Wolverine Trading's BioMarin Pharmaceuticals position peaked at $1.76M in Q4 2021.
- 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.